ClinicalTrials.gg
Sign In

Drug

Anti-PD-1/CD47 Fusion Protein HX009 clinical trials

Also written HX009.

studies test it
4
open now
1
in phase 3
0
first study started
2019

Keep track of what changes. Save the Anti-PD-1/CD47 Fusion Protein HX009 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Development codes

HX009
3

Combined with it in one product

HX009+IN10018
1

Studies by the year they started

4 studies that test it; most in 2019 (1)

Studies that test Anti-PD-1/CD47 Fusion Protein HX009, by start year
YearStudies
20191
20201
20211
20251

By phase

A phase 1/2 study counts in both.

Phase 1
3
Phase 2
2

What it is tested for

Each study’s main condition, where its own words name it.

Neoplasms
2
Biliary Tract Neoplasms
1

Who runs them

Industry 4 · Other 0

Hangzhou Hanx Biopharmaceuticals, Ltd. (3) · Waterstone Hanxbio Pty Ltd (1)

Often tested with

Tested in the same studies.

Ifebemtinib (1)

Studies

Open first, then newest update. How each study uses Anti-PD-1/CD47 Fusion Protein HX009 is read from its arms, and is right about nine times in ten.

Testing it · 4